Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase

Noelle S. Williams, Stephen Gonzales, Jacinth Naidoo, Giomar Rivera-Cancel, Sukesh Voruganti, Prema Mallipeddi, Panayotis C. Theodoropoulos, Sophie Geboers, Hong Chen, Francisco Ortiz, Bruce Posner, Deepak Nijhawan, Joseph M. Ready

Research output: Contribution to journalArticlepeer-review

Abstract

A series of N-acyl benzothiazoles shows selective and potent cytotoxicity against cancer cell lines expressing cytochrome P450 4F11. A prodrug form is metabolized by cancer cells into an active inhibitor of stearoyl-CoA desaturase (SCD). Substantial variation on the acyl portion of the inhibitors allowed the identification of (R)-27, which balanced potency, solubility, and lipophilicity to allow proof-of-concept studies in mice. The prodrugs were activated inside the tumor, where they can arrest tumor growth. Together, these observations offer promise that a tumor-activated prodrug strategy might exploit the essentiality of SCD for tumor growth, while avoiding toxicity associated with systemic SCD inhibition.

Original languageEnglish (US)
Pages (from-to)9773-9786
Number of pages14
JournalJournal of Medicinal Chemistry
Volume63
Issue number17
DOIs
StatePublished - Sep 10 2020

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase'. Together they form a unique fingerprint.

Cite this